

ANNUAL REPORT 2020

Broadview Ventures, Inc. | 265 Franklin Street, Suite 1902 | Boston MA, 02110 | broadviewventures.org | 617.459.4686

2020 PORTFOLIO MOMENTUM

- Our portfolio companies raised \$318M in co-investments, follow-on financings, and grants
- The technologies of Broadview's portfolio companies have touched the lives of more than 180,000 patients to date
- Our co-investors included Novo Seeds, Vensana Capital, Hatteras Venture Partners, Polaris Partners, Xeraya Capital, aMoon Fund, Acorn BioVentures, Danish Growth Fund, BioStar Capital, Catalyst Health Ventures, S3 Ventures, Rev1 Ventures, Viva BioInnovator, BERNINA BioInvest, and 4See Ventures
- The Broadview pipeline remains robust with more than 400 investment opportunities considered in 2020

NEW INVESTMENTS

- Antag Therapeutics—Glucose-dependent insulinotropic peptide receptor antagonist for inducing weight loss in patients with obesity and Type 2 Diabetes
- Basking Biosciences—Reversible aptamer targeting von Willebrand Factor for acute ischemic stroke thrombolysis
- HAYA Therapeutics—Long noncoding RNA-targeting antifibrotic therapeutics for heart failure




Longview Ventures, a \$100M fund dedicated to making follow-on investments in select Broadview portfolio companies, made two investments:

- AtaCor Medical—Extravascular pacing and defibrillation system; raised \$25M Series B for continued clinical development
- Alleviant Medical—Implant-free interatrial shunt system; raised \$20M Series B to fund first-inhuman and additional clinical studies


TALENT

We are pleased to announce the appointment of **Hugh Watkins**, **MD**, **PhD**, to the Broadview Ventures Strategic Advisory Board. Hugh is the Radcliffe Professor of Medicine and Head of the Radcliffe Department of Medicine at the University of Oxford and Honorary Consultant in Cardiology at John Radcliffe Hospital.

BROADVIEW'S INVESTMENTS ARE LEVERAGED 15.5X BY CO-INVESTMENTS, FOLLOW-ON FINANCINGS, AND GRANT FUNDING



BROADVIEW INVESTMENTS BY INDICATION



INVESTMENTS THROUGH 2020

Company	Technology/Therapy	Founders/Management
2020		
Antag Therapeutics Basking Biosciences HAYA Therapeutics	GIPR antagonist for obesity in T2DM population reversible anti-vWF aptamer for acute ischemic stroke IncRNA-targeting antifibrotic therapeutics for heart failure	Alexander Sparre-Ulrich, Mette Rosenkilde, Jens Juul Holst Richard Shea, Shahid Nimjee, Bruce Sullenger Samir Ounzain, Daniel Blessing, Robert Williamson
2019 ————————————————————————————————————	atrial shunt for the treatment of heart failure gene therapy for a rare, familial form of dilated cardiomyopathy	Jacob Kriegel, Adam Berman Maggie Cook, Arthur Feldman
CroíValve 2018 —	percutaneously implanted device for tricuspid regurgitation	Lucy O'Keeffe, Martin Quinn
AtaCor Medical Kantum Pharma	leadless extravascular pacing system for bradycardia P2Y14 antagonists to ameliorate and prevent sterile inflammation	Rick Sanghera, Sean McGeehan, Alan Marcovecchio Sylvie Breton, Glenn Batchelder
2017 — Nido Mellitus Adient	device for epicardial ablation of ventricular tachycardia novel biomarker for the screening and diagnosis of gestational diabetes bioresorbable IVC filter for prevention of pulmonary embolism	Pedro del Nido, Nikolay Vasilyev, Thomas Marchand Jose Halperin, Michael Chorev Mitch Eggers, Joseph Steele
Vectorious EP Sciences	miniature wirelessly-powered implantable left atrial pressure sensor novel defibrillation waveform to reduce pain associated with ICD therapies	Oren Goldshtein, Eyal Orion
2016 FineHeart Gila Therapeutics	fully implantable, miniaturized circulatory support device for HF PYY agonist for management and treatment of obesity	Arnaud Mascarell, Stephane Garrigue, Jean-Luc Boulnois Tom Vasicek
Aeromics 2015 —	novel drug candidate for stroke-related cerebral edema	Tom Zindrick, Trevor Thompson, Marc Pelletier
Pulmokine* Lyra Therapeutics Epirium	small molecule for pulmonary artery hypertension bioresorbable stent for multiple indications mitochondrial biogenesis platform technology	Larry Zisman, Shreefal Mehta Bob Langer, George Whitesides, Maria Palasis George Schreiner, Sundeep Dugar, Russell Cox
ZZ Biotech Ischemia Care	peptide therapeutic for stroke gene-based diagnostic for stroke	Berislav Zlokovic, Kent Pryor, Joseph Romano Jeff June
Acesion Pharma Aria CV	small molecule therapeutic for AF device for pulmonary hypertension	Ulrik Sørensen, Morten Grunnet, Jørgen Søberg Petersen John Scandurra, Karl Vollmers, Dan Gladney
Zumbro Discovery BioKier	peptide therapeutic for treatment of resistant hypertension small molecule anti-diabetic treatment	John Burnett, Horng Chen George Szewczyk, Roger Nolan
Remedy* GI Windows*	small molecule for the treatment of central nervous system edema non-surgical approach to gastric bypass	Sven Jacobson Chris Thompson, Marvin Ryou
VGS InfoBionic	external support for saphenous vein grafts in CABG cloud-based remote arrhythmia monitoring	Eyal Orion Jeremy Ruskin, Stuart Long
Herantis DecImmune	VEG-F based gene therapy for lymphedema MAb for treatment of post MI and I/R injury	Craig Cook Christopher Mirabelli, Walter Newman
Cardialen NuPulse	implantable cardioversion for the treatment of AF counterpulsation device for the treatment of HF	Igor Efimov, Jeff Peters Valluvan Jeevanandam, Douglas Altschuler
Aggamin Provasculon* Apama*	novel preeclampsia treatment peptide therapeutics for treatment of MI and I/R injury novel ablation system for treatment of AF	Ravi Thadhani, Paul Kussie, Ananth Kamuranchi Rich Lee, Roger Kitterman Amr Salahieh
2010 Allosteros Intravascular Imaging	CaMKII inhibitors for HF and AF NIRF device for intracoronary artery imaging	Howard Schulman, Mark Anderson Farouc Jaffer, Vasilis Ntziachristos
Capricor* CellAegis	allogeneic stem cell therapy after MI remote ischemic conditioning for MI	Eduardo and Linda Marbán Andrew Redington, Chris Calderone, Rocky Ganske
2009 CardiAQ Valve* VentriNova	transcatheter mitral valve gene therapy for regeneration of cardiac tissue	Brent Ratz, Arshad Quadri, Rob Michiels Hina Chaudhry
miRagen*	microRNAs for cardiovascular and oncology indications	Bruce Booth, Mike Bristow, Eric Olson

* Exited



BROADVIEW VENTURES TEAM

MANAGEMENT

Christopher Colecchi Managing Director

Maria Berkman, MD Christopher de Souza, PhD Daniel Gottlieb Benjamin Kreitman Hewmun Lau David Milan, MD Nichole Neal Tom Needham

ADVISORS

Annabel Chen-Tournoux, MD Teo Dagi, MD Marc Semigran, MD Viviany Taqueti, MD, MPH Sunny Varshney, MD

STRATEGIC ADVISORY BOARD

Eugene Braunwald, MD Kim Fox, MD Thomas Hughes, PhD Constantino ladecola, MD Jerry Karabelas, PhD Martín Landaluce Joseph Loscalzo, MD, PhD Eric Rose, MD David Tancredi, MD, PhD Hugh Watkins, MD, PhD



LONGVIEW VENTURES INVESTMENT ADVISORY COMMITTEE

EXTERNAL MEMBERS

Terry McGuire Chris Mirabelli, PhD Eric Rose, MD

LEDUCQ MEMBERS

Martín Landaluce David Milan, MD David Tancredi, MD, PhD